Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease

References

• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38.
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). Bonekey Rep. 2014;3:498.
   PubMedGoogle Scholar
• Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.
   PubMed Web of Science ®Google Scholar
• Nicola LD, Zoccali C. Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant. 2016;31:331–335.
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100.
   PubMed Web of Science ®Google Scholar
• LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005;45:1026–1033.
   PubMed Web of Science ®Google Scholar
• Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–1013.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S84–S89.
   Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;S22–S31.
   Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930.
   PubMed Web of Science ®Google Scholar
• Ross A, Manson J, Abrams S, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–58.
   PubMed Web of Science ®Google Scholar
• Helvig CF, Cuerrier D, Hosfield CM, et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int. 2010;78:463–472.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Silva AL, Al-Saghir F, et al. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014;40:535–545.
   PubMed Web of Science ®Google Scholar
• Fernandez-Juarez G, Luno J, Barrio V, et al. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol. 2013;8:1870–1876.
   PubMed Web of Science ®Google Scholar
• Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75:88–95.
   PubMed Web of Science ®Google Scholar
• Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;913–921.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Pi G. Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2016;31:706–713.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1529–1539.
   PubMed Web of Science ®Google Scholar
• de Boer IH, Thadhani R. Vitamin D deficiency: consequence or cause of CKD? Clin J Am Soc Nephrol. 2013;8:1844–1846.
   PubMed Web of Science ®Google Scholar
• Paloian NJ, Giachelli CM. A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol. 2014;307:F891–F900.
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes (KDIGO) 2017 clinical practice guideline update for the diagnosis, evaluation, prevention and treatment of chronic kidney disease – mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:S1–S59.
   PubMed Web of Science ®Google Scholar
• Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53:197–207.
   PubMed Web of Science ®Google Scholar
• Haddad JG Jr., Rojanasathit S. Acute administration of 25-hydroxycholecalciferol in man. J Clin Endocrinol Metab. 1976;42:284–290.
   PubMed Web of Science ®Google Scholar
• Bordier PJ, Marie PJ, Arnaud CD. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol. Kidney Int Suppl. 1975 Jan;(2):S102–112.
   Google Scholar
• Letteri JM, Kleinman LM, Ellis KN, et al. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure. Adv Exp Med Biol. 1977;81:591–601.
   PubMedGoogle Scholar
• Fournier A, Idrissi A, Sebert JL, et al. Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3. Kidney Int Suppl. 1988;24:S178–179.
   PubMedGoogle Scholar
• Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44:316–325.
   PubMed Web of Science ®Google Scholar
• Petkovich M, Melnick J, White J, et al. Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation. J Steroid Biochem Mol Biol. 2015;148:283–289.
   PubMed Web of Science ®Google Scholar
• Bikle DD. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev. 1992;13:765–784.
   PubMed Web of Science ®Google Scholar
• Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21:319–329.
   PubMed Web of Science ®Google Scholar
• DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:1689S–1696S.
   PubMed Web of Science ®Google Scholar
• Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78:1193–1231.
   PubMed Web of Science ®Google Scholar
• Arnaud SB, Goldsmith RS, Lambert PW, et al. 25-Hydroxyvitamin D3: evidence of an enterohepatic circulation in man. Proc Soc Exp Biol Med. 1975;149:570–572.
   PubMed Web of Science ®Google Scholar
• Compston JE, Merrett AL, Ledger JE, et al. Faecal tritium excretion after intravenous administration of 3H-25-hydroxyvitamin D3 in control subjects and in patients with malabsorption. Gut. 1982;23:310–315.
   PubMed Web of Science ®Google Scholar
• Ledger JE, Watson GJ, Compston JE. Biliary excretion of radioactivity after intravenous administration of [3H]25-hydroxyvitamin D3 in man. Dig Dis Sci. 1986;31:361–368.
   PubMed Web of Science ®Google Scholar
• Avioli LV, Birge S, Lee SW, et al. The metabolic fate of vitamin D3-3H in chronic renal failure. J Clin Invest. 1968;47:2239–2252.
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4:1065–1074.
   PubMed Web of Science ®Google Scholar
• Freedman BI. End-stage renal failure in African Americans: insights in kidney disease susceptibility. Nephrol Dial Transplant. 2002;17:198–200.
   PubMed Web of Science ®Google Scholar
• Adams JS, Rafison B, Witzel S, et al. Regulation of the extrarenal CYP27B1-hydroxylase. J Steroid Biochem Mol Biol. 2014;144:22–27.
   PubMed Web of Science ®Google Scholar
• Dusso A, Finch J, Delmez J, et al. Extrarenal production of calcitriol. Kidney Int. 1990;38(29):S36–S40.
   Google Scholar
• Ennis JL, Worcester EM, Coe FL. Sprague SM. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. Nephrol. 2016;29:63–70.
   Web of Science ®Google Scholar
• Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005;135:317–322.
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D for health and in chronic kidney disease. Sem Dial. 2005;18:266–275.
   PubMed Web of Science ®Google Scholar
• Jones G. The pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582S–586S.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. J Am Med Assoc. 2012;307:674–684.
   PubMed Web of Science ®Google Scholar
• Wang AY-M, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD: the OPERA trial. J Am Soc Nephrol. 2014;25:175–186.
   PubMed Web of Science ®Google Scholar
• Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263–276.
   PubMed Web of Science ®Google Scholar
• Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidisim associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43:877–890.
   PubMed Web of Science ®Google Scholar
• Hamdy NAT, Kanis JA, Beneton MNC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Brit Med J. 1995;310:358–363.
   PubMed Web of Science ®Google Scholar
• Coyne D, Goldberg S, Faber M, et al. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014;9:1620–1626.
   PubMed Web of Science ®Google Scholar